Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy.
Chalmers ZR, Ali SM, Ohgami RS, Campregher PV, Frampton GM, Yelensky R, Elvin JA, Palma NA, Erlich R, Vergilio JA, Chmielecki J, Ross JS, Stephens PJ, Hermann R, Miller VA, Miles CR.
Chalmers ZR, et al. Among authors: ohgami rs.
Blood Cancer J. 2015 Feb 6;5(2):e278. doi: 10.1038/bcj.2014.95.
Blood Cancer J. 2015.
PMID: 25658984
Free PMC article.
No abstract available.